Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$48.67+0.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Rigel aims for full-year revenue near $282.5 million in 2026. It targets net product sales around $260 million. The company recently secured a global license for VEPPANU TM, expanding its product pipeline. Its stock trades cheaply with a price-to-earnings ratio of 6.76, well below peers.
Revenue declined from $69.8 million in Q4 2025 to $58.8 million in Q1 2026. The company missed earnings multiple times in 2026. A key license agreement was terminated by a partner, showing risk in collaborations.
The market prices in about 7% revenue growth and a fair value near $84, roughly 51% above the current price. Our view aligns with this but sees risk in execution and growth consistency.
Breaks if: Net product sales fall below $255 million in FY26
Breaks if: Revenue falls below $275 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis is intact, supported by strong recent financial performance, but it carries risks due to the fragile earnings quality and recent earnings misses.
The market seems to price RIGL as cheap compared to its peers, with a notable expectations gap. This suggests that investors may not fully anticipate the potential volatility in earnings or the risks associated with management execution.
Fundamentals may continue to show strong revenue growth as management is on track to meet their revenue guidance. However, the recent earnings miss raises concerns about the company's execution quality, which could impact future performance.
The thesis hinges on management's ability to deliver on revenue guidance and successfully launch VEPPANU. Additionally, the performance of sector bellwethers and overall economic conditions will be critical in determining RIGL's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The launch of Veppanu supports growth expectations and revenue guidance. However, the latest earnings miss raises concerns about execution quality.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Continue to meet full-year total revenue guidance of approximately $275 to $290 million for 2026.
Breaks if: Failure to progress VEPPANU TM development or commercialization by end 2026
Advance development and commercial launch of VEPPANU (vepdegestrant), the first FDA-approved PROTAC for ER+/HER2-, ESR1-mutated metastatic breast cancer.
Newly stated in 2026-Q2. Management completed the exclusive license agreement for VEPPANU in June 2026 and expects U.S. commercial availability in mid-August 2026. This is a recent strategic product expansion with launch activities initiated, showing early delivery on the stated priority.
“Expanded commercial portfolio with the in-license of VEPPANU, with U.S. commercial availability expected in mid-August”
Over the next 1 to 3 years, RIGL's performance will depend on execution and sector dynamics. Not investment advice.